+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Contrast Induced Nephropathy - Pipeline Review, H1 2020

  • ID: 4997666
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 45 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • Pharming Group NV
  • Radikal Therapeutics Inc
  • Saghmos Therapeutics Inc
  • MORE
Contrast Induced Nephropathy - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Contrast Induced Nephropathy - Pipeline Review, H1 2020, provides an overview of the Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline landscape.

Contrast-induced nephropathy (CIN) is defined as the impairment of renal function (measured as either a 25%increase in serum creatinine (SCr) from baseline or a 0.5 mg/dL (44 µmol/L) increase in absolute SCr value after 48-72 hrs contrast administration). Symptoms include feeling more tired, poor appetite, swelling in the feet and ankles,puffiness around the eyes, or dry and itchy skin. Risk factors include age, diabetes, decreased kidney function and congestive heart failure. Treatment includes electrolyte management.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Contrast Induced Nephropathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Contrast Induced Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 3 and 1 respectively.

Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • Pharming Group NV
  • Radikal Therapeutics Inc
  • Saghmos Therapeutics Inc
  • MORE
Introduction
Report Coverage
Contrast Induced Nephropathy - Overview
Contrast Induced Nephropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Contrast Induced Nephropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Contrast Induced Nephropathy - Companies Involved in Therapeutics Development
Daiichi Sankyo Co Ltd
Pharming Group NV
Radikal Therapeutics Inc
Saghmos Therapeutics Inc
Contrast Induced Nephropathy - Drug Profiles
carperitide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
conestat alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
R-911 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-62516 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Contrast Induced Nephropathy - Dormant Projects
Contrast Induced Nephropathy - Discontinued Products
Contrast Induced Nephropathy - Product Development Milestones
Featured News & Press Releases
Oct 17, 2018: Pharming reports positive data from first investigator-initiated study of rhC1-Inhibitor (RUCONEST) in Contrast-induced Nephropathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Contrast Induced Nephropathy, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Contrast Induced Nephropathy - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Contrast Induced Nephropathy - Pipeline by Pharming Group NV, H1 2020
Contrast Induced Nephropathy - Pipeline by Radikal Therapeutics Inc, H1 2020
Contrast Induced Nephropathy - Pipeline by Saghmos Therapeutics Inc, H1 2020
Contrast Induced Nephropathy - Dormant Projects, H1 2020
Contrast Induced Nephropathy - Discontinued Products, H1 2020

List of Figures
Number of Products under Development for Contrast Induced Nephropathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Daiichi Sankyo Co Ltd
  • Pharming Group NV
  • Radikal Therapeutics Inc
  • Saghmos Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll